Diamyd Medical

About Diamyd Medical

Diamyd Medical AB is a Swedish biotechnology company developing immunotherapies for type 1 diabetes. Their lead product, Diamyd®, is in clinical development to preserve insulin production. The company was founded in 1984 and is headquartered in Stockholm.

Kategori

All

Coverage comment

Summary

Podcasts

2025-05-05

Coverage comment Diamyd Medical - Successful capital raising

Impala Nordic comments on the outcome of the rights issue in Diamyd Medical AB and considers the result, which shows an oversubscription of 108 percent, to be very impressive.

The company will receive SEK 224 million before issue costs through the rights issue, which are considered low as the issue was carried out without any guarantee commitments. In addition, the company has carried out a directed new issue to selected investors of SEK 41.6 million, which further strengthens the cash position.

2025-04-17

Impala Nordic has prepared a summary of the investment case in Diamyd Medical AB (publ)

Diamyd Medical is a biotechnology company that develops precision medicine therapies for the prevention and treatment of autoimmune type 1 diabetes.

The Company is currently conducting a rights issue of SEK 208 million to secure capital ahead of the early readout of the Company's Phase 3 study DIAGNODE-3 in March 2026.

Read the investment case

2024-07-08

FinVoices: Ulf Hannelius, CEO of Diamyd Medical AB (publ)

Ulf shares his background in molecular biology and experience in the biotechnology industry, as well as providing an overview of Diamyd Medical.

Ulf discusses the progress of the DIAGNODE-3 study, the importance of the FDA Fast Track designation, and the benefits of intralymphatic immunotherapy. He also provides an update on the production facility in Umeå, the company's financing situation, and concludes by answering listener questions.

Listen to podcast episode

2024-05-14

FinVoices: Chris Nowak on the project, the future and investments in life science

Christoph Nowak, MD, PhD, board member at OncoZenge AB (publ), shares his journey in the pharmaceutical and research industry.

The episode discusses current treatment options for oral mucositis and why BupiZenge represents a significant advance in the field. We also take a look at Chris' other roles as Chief Medical and Business Officer at Diamyd Medical AB (publ) and Melius Pharma.

Listen to podcast episode